Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Source: SeekingAlpha
2026-05-18 09:28:12 ET
In my March article, "Why Pfizer Remains A Strong Buy In 2026" , I mainly discussed Pfizer's Q4 earnings ( PFE ) and the efficacy of Ibrance's successor, called atirmociclib, in the Phase 2 FOURLIGHT-1 study ....
Read the full article on Seeking Alpha
For further details see:
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Alnylam Pharmaceuticals Inc.
NASDAQ: ALNY
ALNY Trading
1.21% G/L:
$289.93 Last:
247,711 Volume:
$284.48 Open:
ALNY Latest News
June 03, 2026 04:45:00 pm
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
ALNY Stock Data
$42,146,950,218
131,611,785
0.16%
379
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
